ProCE Banner Activity

Current Essential Testing in Early Breast Cancer: A Focus on BRCA Testing and Adjuvant PARP Inhibition

Clinical Thought
BRCA testing is now essential to identify patients with early breast cancer who may benefit from adjuvant olaparib.

Released: November 17, 2022

Expiration: November 16, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

ProCE

ProCE Banner

Faculty Disclosure

Primary Author

Charles E. Geyer, Jr., MD

Professor of Medicine
Division of Hematology/Medical Oncology
Department of Internal Medicine
University of Pittsburgh UPMC Hillman Cancer Center
Staff Attending
Breast Medical Oncology
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania

Charles E. Geyer, Jr., MD: researcher: AbbVie, AstraZeneca, Daiichi Sankyo, Roche/Genentech; consultant/advisor/speaker: Exact Sciences, SeaGen.